37025-55-1 Usage
Description
(BUTYRYL1,TYR(ME)2)-1-CARBAOXYTOCIN TRIFLUOROACETATE SALT is a synthetic analog of oxytocin, a hormone that plays a crucial role in various physiological processes, including childbirth and lactation. This specific compound is characterized by the substitution of certain functional groups in the oxytocin molecule, which may result in altered properties or enhanced efficacy. It is a carba-analogue of oxytocin, where the sulfur of the cysteine residue is replaced by a methylene group, and the hydrogen on the phenolic hydroxy group is substituted by methyl. Additionally, the amino group on the cysteine residue is substituted by hydrogen.
Uses
Used in Obstetric Applications:
(BUTYRYL1,TYR(ME)2)-1-CARBAOXYTOCIN TRIFLUOROACETATE SALT is used as an obstetric drug for controlling postpartum hemorrhaging. As an oxytocin receptor agonist, it stimulates the contraction of the uterus, effectively managing bleeding after childbirth. Its long-acting and rapid onset of action make it a valuable alternative to traditional oxytocin treatments.
Used in Lactation Stimulation:
(BUTYRYL1,TYR(ME)2)-1-CARBAOXYTOCIN TRIFLUOROACETATE SALT is also used to stimulate milk let-down due to its action on oxytocin receptors of myoepithelial cells. This application can be particularly beneficial for mothers who may experience difficulties in initiating or maintaining lactation.
Biochem/physiol Actions
Carbetocin is a potent agonist of the oxytocin receptor, with improved in vivo stability over oxytocin.
Check Digit Verification of cas no
The CAS Registry Mumber 37025-55-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,7,0,2 and 5 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 37025-55:
(7*3)+(6*7)+(5*0)+(4*2)+(3*5)+(2*5)+(1*5)=101
101 % 10 = 1
So 37025-55-1 is a valid CAS Registry Number.
InChI:InChI=1/C45H69N11O12S/c1-6-25(4)38-44(67)50-28(15-16-34(46)58)40(63)51-30(21-35(47)59)41(64)53-31(23-69-18-8-10-37(61)55(5)33(43(66)54-38)20-26-11-13-27(57)14-12-26)45(68)56-17-7-9-32(56)42(65)52-29(19-24(2)3)39(62)49-22-36(48)60/h11-14,24-25,28-33,38,57H,6-10,15-23H2,1-5H3,(H2,46,58)(H2,47,59)(H2,48,60)(H,49,62)(H,50,67)(H,51,63)(H,52,65)(H,53,64)(H,54,66)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1
37025-55-1Relevant articles and documents
PROCESS FOR LARGE SCALE LIQUID PHASE SYNTHESIS OF CARBETOCIN AND ITS NOVEL INTERMEDIATES
-
Page/Page column 11; 25, (2017/11/06)
A process for large scale liquid phase synthesis of Carbetocin is disclosed. Novel intermediates of formula (A), formula (B), and processes for their preparation are also disclosed.
